Veterinary Intravenous (IV) Solutions Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Isotonic crystalloids, Synthetic colloids, Blood products, Dextrose solutions, Parenteral nutrition), By Indication (Diabetic Ketoacidosis, Pancreatitis, Anthrax, Chronic Kidney Disease, Others), By Animal type (Companion Animals, Production Animals), By End Use (Veterinary Hospitals, Research Institutes, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.51 Billion
CAGR (2026-2031)	6.63%
Fastest Growing Segment	Companion Animal
Largest Market	North America
Market Size (2031)	USD 2.22 Billion

Market Overview

The Global Veterinary Intravenous (IV) Solutions Market is projected to grow from USD 1.51 Billion in 2025 to USD 2.22 Billion by 2031 at a 6.63% CAGR. Veterinary intravenous (IV) solutions encompass sterile fluid preparations administered parenterally to animals for purposes such as hydration, electrolyte balance, nutrient delivery, and medication administration. The market's expansion is fundamentally supported by increasing global companion animal ownership and the intensifying trend of pet humanization, which drives demand for advanced veterinary medical care. Furthermore, a rising incidence of various animal diseases necessitating critical and supportive treatments contributes significantly to market growth. According to HealthforAnimals, the top 20 global animal health companies generated a combined revenue of $38.6 billion in 2024.

A significant challenge that could hinder market expansion involves the complexities associated with managing global supply chain disruptions for pharmaceutical-grade raw materials and finished IV solutions. Such disruptions can result in product shortages and escalate operational costs for veterinary clinics and hospitals globally.

Key Market Drivers

The rising incidence of various animal diseases profoundly influences the Global Veterinary Intravenous (IV) Solutions Market by escalating the need for diagnostics, treatment, and supportive care that often requires fluid administration. As veterinarians increasingly manage complex and chronic conditions, the demand for IV solutions for rehydration, electrolyte balance, nutrient delivery, and medication infusion grows. Many prevalent conditions necessitate extended or repeated courses of IV therapy, whether for acute illness stabilization, post-surgical recovery, or the ongoing management of long-term health issues. For example, findings from Nationwide Pet Insurance indicate that chronic conditions constituted six out of the top ten health problems for dogs and seven out of the top ten for cats in 2024, highlighting the persistent and often intensive care requirements for companion animals.

The increasing pet ownership rates globally, coupled with the profound trend of pet humanization, significantly drive the demand for advanced veterinary medical care, including IV solutions. Owners increasingly view their pets as integral family members, leading to a greater willingness to invest in sophisticated treatments, emergency services, and complex surgical procedures when necessary. This elevated emotional bond translates into higher veterinary healthcare expenditure, supporting the adoption of comprehensive medical interventions. Reflecting this trend, U.S. pet spending reached $158 billion in 2025, a 3.7% increase from the previous year, according to the American Pet Products Association. This financial commitment enables veterinarians to utilize a broader range of therapeutic options, including specialized IV formulations. Overall, the animal health industry continues to demonstrate substantial economic activity, with a major player like Zoetis reporting full-year 2024 revenue of $9.3 billion.

Download Free Sample Report

Key Market Challenges

Global supply chain disruptions represent a substantial impediment to the expansion of the veterinary intravenous (IV) solutions market. These complexities arise from challenges in procuring pharmaceutical-grade raw materials and ensuring the timely delivery of finished IV solutions. Such disruptions directly contribute to product shortages across veterinary clinics and hospitals worldwide, compelling practitioners to manage reduced availability of critical treatments. Moreover, the inherent volatility within these supply chains escalates operational costs for veterinary care providers.

The significance of these challenges is underscored by the proactive measures taken by industry bodies. According to the Federation of Veterinarians of Europe (FVE) in its 2025 Annual Report, the organization responded to 60 consultations during the year, with fostering the availability of essential medicines listed as a core policy priority. This high level of engagement reflects the widespread impact of supply chain issues on the accessibility and affordability of vital veterinary pharmaceutical products, directly hindering the consistent provision of care and, consequently, market growth for IV solutions.

Key Market Trends

Advancements in IV fluid delivery systems and monitoring technologies represent a significant trend, enhancing the precision and safety of fluid administration in veterinary patients. These innovations include smart infusion pumps that offer highly accurate flow rates and integrate with patient monitoring to provide real-time data, thereby enabling veterinarians to make immediate, informed adjustments to therapy. The improved capabilities of these systems contribute to better patient outcomes, especially in delicate cases where even small errors in fluid management can have serious consequences. For instance, according to IDEXX Laboratories' Fourth Quarter and Full Year 2025 Results, released February 2, 2026, CAG Diagnostics capital instrument revenues expanded 69% on an organic basis, indicating a growing investment in advanced diagnostic and monitoring equipment that supports comprehensive critical care.

The mainstreaming of balanced isotonic crystalloids signifies another key trend, driven by a deeper understanding of animal physiology and the desire to minimize complications associated with less physiologically appropriate fluids. These solutions, designed to mimic the electrolyte composition of plasma, help maintain acid-base balance and reduce the risk of adverse effects such as hyperchloremic acidosis. Their increasing adoption reflects a shift towards more refined and individualized fluid therapy protocols in daily veterinary practice and critical care settings. The importance of optimizing foundational care is highlighted by challenges in patient management, as an article in Today's Veterinary Practice, April 14, 2025, in "Preventing Malnutrition in Critical Care Patients," reported that an investigation of 276 hospitalized dogs found a positive energy balance was achieved for only 27% of dog-days, underscoring the ongoing need for comprehensive and physiologically sound patient support, including fluid therapy.

Segmental Insights

The Companion Animal segment is currently the fastest-growing within the Global Veterinary Intravenous (IV) Solutions Market. This rapid expansion is primarily driven by the increasing humanization of pets, where companion animals are increasingly regarded as integral family members, prompting owners to significantly invest in their health and welfare. This profound shift in owner perception, combined with the wider adoption of pet insurance, enhances access to advanced veterinary medical care, encompassing critical care, surgical procedures, and various disease management protocols where intravenous solutions are crucial for hydration, medication delivery, and nutritional support. Consequently, the demand for specialized IV solutions tailored for companion animals is experiencing substantial growth.

Regional Insights

North America consistently leads the global veterinary intravenous solutions market due to several key factors. The region benefits from a high rate of pet ownership and the prevalent trend of pet humanization, driving increased expenditure on advanced veterinary healthcare services. This commitment to animal wellness is further supported by robust animal healthcare infrastructure and widespread access to sophisticated veterinary facilities. Additionally, the rising incidence of chronic and acute diseases in companion animals necessitates extensive intravenous therapies. High pet insurance adoption also enables owners to pursue comprehensive treatment options, reinforcing demand for these critical solutions across the region.

Recent Developments

• In January 2026, the FDA approved the first generic Florfenicol and Flunixin Meglumine Injection. This new generic injectable product is indicated for the treatment of bovine respiratory disease and associated pyrexia in beef and non-lactating dairy cattle. The introduction of this combination therapy offers veterinarians an additional tool for managing severe conditions in livestock, with injectable medications playing a critical role in treatment regimens often involving intravenous administration.
• In August 2025, new discoveries in veterinary medicine highlighted the development of targeted treatments, such as monoclonal antibodies (mAbs), for various animal diseases. These advanced therapies, which help a pet's immune system combat specific diseases, often necessitate intravenous administration. This breakthrough in therapeutic options influences the Global Veterinary Intravenous (IV) Solutions Market by driving demand for the associated delivery systems and support fluids essential for administering such specialized treatments.
• In March 2025, Parnell launched PropofolVet Multidose, a new generic propofol injectable emulsion for dogs. This anesthetic injection is designed for veterinary use, supporting induction anesthesia and the maintenance of general anesthesia through intermittent bolus injections for short procedures. Veterinarians can also utilize this product when anesthesia maintenance is provided by inhalant anesthetics. This new product provides an option within the veterinary intravenous solutions market, specifically for agents administered via IV.
• In 2026, Boehringer Ingelheim and Eko Health entered a digital partnership to launch a dedicated mobile application leveraging AI-powered stethoscope technology for canine cardiology. This collaboration, while focused on diagnostics, directly impacts the management of canine cardiac patients. These animals frequently require complex fluid management and other intravenous interventions, underscoring the indirect but significant relationship to the Global Veterinary Intravenous (IV) Solutions Market in supporting patient care strategies.

Key Market Players

• Baxter International Inc.
• B. Braun SE
• ICU Medical, Inc.
• Fresenius Kabi AG
• Dechra Pharmaceuticals PLC
• Zoetis Inc.
• Elanco Animal Health Incorporated
• Virbac S.A.
• Vetoquinol S.A.
• Merck & Co., Inc.

By Product	By Indication	By Animal type	By End Use	By Region
Isotonic crystalloids Synthetic colloids Blood products Dextrose solutions Parenteral nutrition	Diabetic Ketoacidosis Pancreatitis Anthrax Chronic Kidney Disease Others	Companion Animals Production Animals	Veterinary Hospitals Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Intravenous (IV) Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Intravenous (IV) Solutions Market, By Product:

• Isotonic crystalloids
• Synthetic colloids
• Blood products
• Dextrose solutions
• Parenteral nutrition

• Veterinary Intravenous (IV) Solutions Market, By Indication:

• Diabetic Ketoacidosis
• Pancreatitis
• Anthrax
• Chronic Kidney Disease
• Others

• Veterinary Intravenous (IV) Solutions Market, By Animal type:

• Companion Animals
• Production Animals

• Veterinary Intravenous (IV) Solutions Market, By End Use:

• Veterinary Hospitals
• Research Institutes
• Others

• Veterinary Intravenous (IV) Solutions Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE